- Home
- CPS vs DSGN Comparison
CPS vs DSGN Comparison
Compare CPS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPS
- DSGN
- Stock Information
- Founded
- CPS 1960
- DSGN 2017
- Country
- CPS United States
- DSGN United States
- Employees
- CPS N/A
- DSGN N/A
- Industry
- CPS Auto Parts:O.E.M.
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- CPS Consumer Discretionary
- DSGN Health Care
- Exchange
- CPS Nasdaq
- DSGN Nasdaq
- Market Cap
- CPS 208.1M
- DSGN 224.8M
- IPO Year
- CPS N/A
- DSGN 2021
- Fundamental
- Price
- CPS $23.04
- DSGN $3.73
- Analyst Decision
- CPS Hold
- DSGN Hold
- Analyst Count
- CPS 1
- DSGN 1
- Target Price
- CPS $12.00
- DSGN $4.00
- AVG Volume (30 Days)
- CPS 573.2K
- DSGN 91.9K
- Earning Date
- CPS 05-01-2025
- DSGN 05-07-2025
- Dividend Yield
- CPS N/A
- DSGN N/A
- EPS Growth
- CPS N/A
- DSGN N/A
- EPS
- CPS N/A
- DSGN N/A
- Revenue
- CPS $2,721,537,000.00
- DSGN N/A
- Revenue This Year
- CPS N/A
- DSGN N/A
- Revenue Next Year
- CPS $5.00
- DSGN N/A
- P/E Ratio
- CPS N/A
- DSGN N/A
- Revenue Growth
- CPS N/A
- DSGN N/A
- 52 Week Low
- CPS $10.38
- DSGN $2.60
- 52 Week High
- CPS $26.73
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- CPS 60.73
- DSGN 48.52
- Support Level
- CPS $21.45
- DSGN $3.31
- Resistance Level
- CPS $24.38
- DSGN $4.13
- Average True Range (ATR)
- CPS 1.18
- DSGN 0.31
- MACD
- CPS -0.41
- DSGN 0.04
- Stochastic Oscillator
- CPS 31.67
- DSGN 61.27
About CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.